Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan

Journal of Infectious Diseases

Volumn 200, Issue SUPPL. 1, 2009, Pages

  Flem, Elmira T ^a   Latipov, Renat ^b   Nurmatov, Zuridin S ^c   Xue, Yiting ^a   Kasymbekova, Kaliya T ^c   Rheingans, Richard D ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b National Reference Laboratory   (Uzbekistan)

^c Ministry of Health   (Kyrgyzstan)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HOSPITALIZATION COST; HUMAN; IMMUNIZATION; INFECTIOUS DIARRHEA; KYRGYZSTAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VACCINATION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DIARRHEA; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; KYRGYZSTAN; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 72849139468     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605040     Document Type: Article

References (23)

1. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285-295
2. Lob-Levyt J. Re: 2007 update on support to countries from the GAVI Alliance. Document GAVI/07/040/ir/hb. GAVI Alliance, March 2007. Available at: http://www.gavialliance.org/resources/GAVI-Letter-Update-Mar07.pdf. Accessed 22 February 2008.
3. Goossens LM, Standaert B, Hartwig N, Hovels AM, Al MJ. The costutility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26:1118-1127
4. Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93:52-58
5. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25:3971-3979 (Pubitemid 46616994)
6. Lorgelly PK, Joshi D, Iturriza GM, Gray J, Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136:44-55.
7. Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001; 10:240-248 (Pubitemid 33064131) (Pubitemid 33064131)
8. Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192:1720-1726 (Pubitemid 41587821) (Pubitemid 41587821)
9. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192(Suppl 1):S133-45.
10. Walker DG, Rheingans R. Cost-effectiveness of rotavirus vaccines.Expert Rev Pharmacoecon Outcomes Res 2005; 5:593-601.
11. Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25:373-380 (Pubitemid 44856079) (Pubitemid 44856079)
12. UNICEF. The state of the worlds children 2008. UNICEF, 2008. Available at: http://www.unicef.org/sowc08/statistics/tables.php. Accessed 22 February 2008
13. McKee M, Healy J, Falkingham J. Health care in central Asia. Buckingham, United Kingdom: Open University Press, 2002.
14. Meimanaliev A-S, Ibraimova A, Elebesov B, Rechel B. Health care systems in transition: Kyrgyzstan. Copenhagen: World Health Organization Regional Office for Europe, on behalf of the European Observatory on Health Systems and Policies, 2005.
15. World Health Organization. WHO-UNICEF estimates of DTP3 coverage. Geneva: World Health Organization, 2007. Available at: http://www.who.int/immunization- monitoring/en/globalsummary/timeseries/tswucoveragedtp3.htm. Accessed 22 February 2008.
16. Griffiths U, Rheingans R, Walker D. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the costs of rotavirus diarrhea. Geneva: World Health Organization, 2005. Available at: http://www.who.int/vaccine-research/documents/Eco-Burden-Diarrhoeal.pdf. Accessed 7 July 2008.
17. Interstate Statistical Committee of the Commonwealth of Independent States. Exchange rates of national currencies established of national (central) banks of the countries of the Commonwealth of Independent States in 2008. Interstate Statistical Committee of the CIS, 2008. Available at: http://www.cisstat.com/eng/index.htm. Accessed 25 May 2008.
18. World Health Organization. Choosing interventions that are cost-effective (WHO-CHOICE). Unit costs for patient services. Geneva: World Health Organization, 2000. Available at: http://www.who.int/choice/costs/unit-costs/en/ index.html. Accessed 7 July 2008.
19. International Monetary Fund.World economic outlook database. April 2008. Available at: http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/weoselgr. aspx. Accessed 7 July 2008.
20. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22. (Pubitemid 43048947) (Pubitemid 43048947)
21. Salinas B, Schael IP, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-816 (Pubitemid 41324890) (Pubitemid 41324890)
22. World Health Organization. The world health report 2002-reducing risks, promoting healthy life. Geneva: World Health Organization, 2002:108.
23. Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination-United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 218-222